NCT04281121 (omega 3) is a NA clinical trial of omega 3 fatty acids in Fatty Liver, sponsored by Ain Shams University.

Who is sponsoring NCT04281121?

NCT04281121 is sponsored by Ain Shams University.

What drugs are being tested in NCT04281121?

Interventions in NCT04281121: omega 3 fatty acids.

What condition does NCT04281121 study?

NCT04281121 studies Fatty Liver.

Is NCT04281121 still recruiting?

NCT04281121 is currently completed. Last updated 24 February 2020.

Last reviewed 2020-02-24 · How we verify

NCT04281121: omega 3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Omega 3 Supplementation in Children With Non Alcoholic Fatty Liver

Completed NA Last updated 24 February 2020

What this trial tests

NA trial testing omega 3 fatty acids in Fatty Liver in 60 participants. Completed in 19 February 2020.

Timeline

1 March 2019

Primary endpoint
25 January 2020

19 February 2020

Quick facts

Lead sponsor	Ain Shams University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 March 2019
Primary completion	25 January 2020
Estimated completion	19 February 2020
Sites	1 location across Egypt

Drugs / interventions tested

omega 3 fatty acids

Conditions studied

Fatty Liver — all drugs for Fatty Liver →

Sponsor

Ain Shams University

Who can join

Adults 6 to 16, any sex, with Fatty Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

this is a prospective, interventional, open-label, randomized study on the efficacy of omega 3 fatty acids supplementation in Egyptian children with non-alcoholic fatty liver disease who had been selected from nutrition and outpatient clinic at Pediatric hospital, Ain Shams University

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
Ezhilarasan D, Lakshmi T. · · 2022 · cited 34× · PMID 35602098 · DOI 10.1155/2022/9233650
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
Komolafe O, Buzzetti E, Linden A, Best LM, et al · · 2021 · cited 12× · PMID 34280304 · DOI 10.1002/14651858.cd013157.pub2
Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
Antonella M, Pietrobattista A, Maggiore G. · · 2024 · cited 6× · PMID 38651464 · DOI 10.3390/pediatric16020025

Verify or expand the search:

Other trials of omega 3 fatty acids

Trials testing the same drug.

NCT02295059 — Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention · NA · active not recruiting

Other recruiting trials for Fatty Liver

Currently open trials in the same condition.

NCT07242222 — Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
NCT07238985 — Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
NCT06989723 — Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes · Phase 4 · recruiting
NCT06203548 — Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter · NA · recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04281121 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 24 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04281121.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing